Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | UTS2R | Q9UKP6 | 7/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.44 |
| ▸ | PDCD1LG2 | Q9BQ51 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241833 | 0.86 | LTA4H (0.54) | LTA4HUTS2RMCHR1CYP2D6TEAD1 | |
| SCHEMBL2236466 | 0.84 | BCHE (0.44) | LTA4HMCHR1CYP2D6 | |
| SCHEMBL2239984 | 0.83 | HDAC1 (0.44) | LTA4H | |
| SCHEMBL2234967 | 0.82 | BCHE (0.47) | LTA4H | |
| SCHEMBL2238595 | 0.81 | ALDH1A1 (0.47) | CYP2D6HRH3 | |
| SCHEMBL1936097 | 0.81 | HTT (0.51) | LTA4HCD274 | |
| SCHEMBL2237327 | 0.80 | ALDH1A1 (0.51) | LTA4H | |
| SCHEMBL2237880 | 0.80 | HTR2C (0.43) | — | |
| SCHEMBL2240256 | 0.79 | OPRM1 (0.43) | LTA4HHRH3 | |
| SCHEMBL2237555 | 0.79 | BCHE (0.54) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | LTA4H 277/4885UTS2R 348/4885MCHR1 344/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | LTA4H 248/4885UTS2R 310/4885MCHR1 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.